key: cord-0858684-hq65uo52
authors: Sweeney, Ann T.; Pena, Samara; Sandeep, Jeena; Hernandez, Bryan; Chen, Ye; Breeze, Janis L.; Bulut, Aysegul; Feghali, Karen; Abdelrehim, Moaz; Abdelazeem, Mohamed; Srivoleti, Padmavathi; Salvucci, Linda; Cann, Susan Berry; Norman, Catalina
title: Use of a Continuous Glucose Monitoring System in High Risk Hospitalized Non-critically ill Patients with Diabetes after Cardiac Surgery and during their Transition of Care from the Intensive Care Unit during Covid-19-A Pilot Study
date: 2022-03-08
journal: Endocr Pract
DOI: 10.1016/j.eprac.2022.03.001
sha: 8cc1cc74a768c70d7ea134e85c8d1650148a5033
doc_id: 858684
cord_uid: hq65uo52

OBJECTIVE: Continuous glucose monitoring (CGM) has demonstrated benefits in managing inpatient diabetes. We initiated this single-arm pilot feasibility study during the COVID-19 pandemic in 11 patients to determine the feasibility and accuracy of real-time CGM in cardiac surgery patients with diabetes after their transition of care from the intensive care unit(ICU). METHODS: Clarke Error Grid(CEG) analysis was used to compare CGM and point-of-care(POC) measurements. Mean absolute relative difference(MARD) of the paired measurements was calculated to assess the accuracy of the CGM for glucose measurements during the first 24 hours on CGM, the remainder of time on the CGM as well as for different chronic kidney disease(CKD) strata. RESULTS: Overall MARD between POC and CGM measurements was 14.80%. MARD for patients without CKD IV and V with eGFR < 20 ml/min/1.73m(2) was 12.13%. Overall, 97% of the CGM values were within the no-risk zone of the CEG analysis. For the first 24 hours, a sensitivity analysis of the overall MARD for all subjects and for those with eGFR > 20 ml/min/1.73m(2) was 15.42% (+/- 14.44) and 12.80% (+/- 7.85) respectively. Beyond the first 24 hours, overall MARD for all subjects and for those with eGFR > 20 ml/min/1.73m(2) was 14.54% (+/- 13.21) and 11.86% (+/- 7.64) respectively. CONCLUSIONS: CGM has great promise to optimize inpatient diabetes management in the noncritical care setting and after the transition of care from the ICU with high clinical reliability, and accuracy. More studies are needed to further assess CGM in patients with advanced CKD.

Overall MARD between POC and CGM measurements was 14.80%. MARD for 10 patients without CKD IV and V with eGFR < 20 ml/min/1.73m 2 was 12.13%. Overall, 97% of 11 the CGM values were within the no-risk zone of the CEG analysis. For the first 24 hours, a 12 sensitivity analysis of the overall MARD for all subjects and for those with eGFR > 20 13 ml/min/1.73m 2 was 15.42% (+/-14.44) and 12.80% (+/-7.85) respectively. Beyond the first 24 14 hours, overall MARD for all subjects and for those with eGFR > 20 ml/min/1.73m 2 was 14.54% 15 (+/-13.21) and 11.86% (+/-7.64) respectively.

Conclusions: CGM has great promise to optimize inpatient diabetes management in the 17 noncritical care setting and after the transition of care from the ICU with high clinical reliability, 18 and accuracy. More studies are needed to further assess CGM in patients with advanced CKD. (ICU) patients [1, [6] [7] [8] [9] [10] [11] [12] and none have focused solely on hospitalized non ICU cardiac surgery 33 patients with diabetes transferred to the surgery ward from the ICU after undergoing 34 cardiovascular surgery (primarily coronary artery bypass grafting). It is well established that 35 patients with diabetes are at higher risk for coronary artery disease compared with the general 36 population and that approximately two-thirds of these patients have multivessel disease. [ greater than 4 grams of acetaminophen in 24 hours were also excluded. The study was approved 64 by our local Institutional Review Board.

In this prospective pilot study, we recruited 11 consecutive patients from our endocrine 66 consultation service who had undergone cardiac surgery, been discharged from the intensive care 67 unit (ICU) and who were transferred to the cardiac transition unit, and who were all on 68 subcutaneous insulin. The primary study outcomes were to assess the feasibility and accuracy of Table 1 . Their mean age (+/-SD) was 72.5 (+/-4.3) years with a 99 mean body mass index (BMI) of 30.6 (+/-5.2) kg/m 2 . Three patients were women and three were 100 minorities. The median A1C (median [IQR]) was 7.8% (7.4%, 10.3%). All patients required 101 basal-bolus insulin therapy pre-and post-operatively. Nine patients (81%) had chronic kidney 102 disease (CKD): stage II (1), stage III (5), Stage IV (2) and stage V (1). Outcomes over 3 days of 103 hospitalization are summarized in Table 2 . The mean CGM glucose was 179 mg/dl and TIR ( % 104 time in range 70-180 mg/dL) was 59.8%. The maximum duration of CGM monitoring per patient 105 was 76 hours.

The CEG analysis and MARD are illustrated in Figure 1 . A total of 137 paired POC-107 CGM measurements were used for analysis. The MARD statistics between CGM and POC blood 108 glucose levels as well as CKD strata are listed in Table 3 . The overall MARD and median ARD 109 between POC and CGM measurements was 14.80% (+/-13.53) and 13.20% (IQR: 5.22%, 110 18.52%) respectively. The MARD for the patients with eGFR > 20ml/min/1.73m 2 was 12.13% 111 (+/-7.67) and for those with eGFR < 20ml/min/1.73m 2 was 21.27% (+/-20.81). A further 112 sensitivity analysis of the overall MARD for all subjects for the first 24 hours and for those with 113 eGFR >20ml/min/1.73m 2 was 15.42% (+/-14.44) and 12.80% (+/-7.85) respectively (Table 4) .

Overall MARD for all subjects beyond the first 24 hours and MARD for those with eGFR 115 >20ml/min/1.73m 2 was 14.54% (+/-13.21) and 11.86% (+/-7.64) respectively.

The CEG analysis ( Figure 1 ) of all matched pair data demonstrated good clinical 117 reliability as we observed that 76.6% of values were within zone A, in which the POC-CGM 118 values were within 20%; 21.2% were within zone B, in which the POC-CGM values differed by 119 more than 20% but there was no effect on clinical outcome, and 2.2% were within upper zone D 120 in which there was undetected hypoglycemia. One study subject had a hypoglycemic excursion 121 J o u r n a l P r e -p r o o f below 70 mg/dl, which was captured on CGM but not on POC blood glucose level. In this 122 instance, the physician noted the CGM alarm and alerted the assigned nurse. particularly the inclusion of patients with eGFR <20 ml/min/1.73m 2 . Two patients, one with 132 advanced stage IV (eGFR < 20 ml/min/1.73m 2 ) and one with stage V CKD (eGFR < 15 133 ml/min/1.73m 2 ; on dialysis) had the most discordance between their POC and CGM blood 134 glucose levels, with each having 7 values differing by >20% and therefore had a higher MARD 135 whereas one patient with CKD IV and eGFR of > 20 ml/min/1.73m 2 had a MARD <5%. V in our study were more prone to hypoglycemia (glucose < 70 mg/dl) and significant anemia 148 (mean hemoglobin 8.2 g/dl) -two circumstances associated with a higher MARD. [2, 3, 9, 10] 149 Inclusion of CGM levels from the first 24 hours after CGM placement also contributed to the 150 higher overall MARD as CGM is known to be less accurate during this period. J o u r n a l P r e -p r o o f Table 2 382 Summary statistics of outcomes over 3 days:

Overall (n=10*) % Time in range 70-180 mg/dL (mean (SD)) 59.8 (22.7) % Time hypoglycemia < 70 mg/dL (mean (SD)) 1.4 (2.0) % Time hypoglycemia < 54 mg/dL (mean (SD)) 0.3 (0.9) % Time hyperglycemia >180 mg/dL (mean (SD)) 38.8 ( 

Teaching points

• Continuous glucose monitoring (CGM) has great potential to improve diabetes management in the inpatient noncritical care setting including during transitions of care. • Regarding the accuracy of CGM, the overall mean absolute relative difference (MARD) between point-of-care (POC) capillary blood glucose levels and CGM measurements was 14.80%. The MARD for patients without chronic kidney disease (CKD) IV and CKD V with estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m 2 was 12.13%. • The MARD is higher in patients with advanced CKD and eGFR < 20 ml/min/1.73m 2 .

• We demonstrated the clinical reliability of CGM as 97% of the CGM values were within the no-risk zone of the Clark Error Grid (CEG) analysis. • CGM provides comprehensive and continuous glucose data which assists in discerning glycemic patterns and aids in insulin treatment adjustments.

Clinical relevance CGM has great promise to optimize inpatient diabetes management in the noncritical care setting and during transitions of care with high clinical reliability and accuracy. This is the first published study that has focused on cardiac surgery patients during their transition of care from the ICU to the ward setting.

The Effect of Continuous Glucose Monitoring in Preventing Inpatient

Hypoglycemia in General Wards: The Glucose Telemetry System

Reducing Inpatient Hypoglycemia in the General Wards Using Real-time 254

Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial. 255 Diabetes Care

Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring 257 (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type

Randomized study of basal-bolus insulin therapy in the inpatient 307 management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care

Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-310 19 Pandemic. Diabetes Care

The original Clarke Error Grid Analysis (EGA)

Measures of Accuracy for Continuous Glucose Monitoring and Blood 314 Glucose Monitoring Devices

Significance and Reliability of MARD for the Accuracy of CGM Systems

Comparison of Interstitial Fluid Glucose Levels Obtained 318 by Continuous Glucose Monitoring and Flash Glucose Monitoring in Patients With Type

Diabetes Mellitus Undergoing Hemodialysis

Use of continuous glucose monitoring system in patients with type 2 321 mellitus diabetic during hemodialysis treatment

Blood glucose fluctuations in hemodialysis patients with end stage diabetic 323 nephropathy

Continuous Glucose Monitoring in the Operating Room and Cardiac 325 Intensive Care Unit. Diabetes Care

Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in 327 the general ward. Diabetes Care

Continuous Glucose Monitors and Automated Insulin Dosing Systems in the 329

Disturbances in Insulin-Glucose Metabolism in Patients With Advanced 331

Renal Disease With and Without Diabetes

Glycemic Monitoring and Management in Advanced Chronic Kidney Disease

Effectiveness of continuous glucose monitoring in dialysis patients with 335 diabetes: the DIALYDIAB pilot study

Remote Continuous Glucose Monitoring With a Computerized Insulin Infusion 337 Protocol for Critically Ill Patients in a COVID-19 Medical ICU: Proof of Concept. Diabetes Care

Clinical decision support to improve management of diabetes and 340 dysglycemia in the hospital: a path to optimizing practice and outcomes

The Association of Diabetes and Hyperglycemia on Inpatient Readmissions

Acknowledgements: We would like to express our sincere gratitude to our dedicated study coordinator, Ms. Aimee Jovino.